Evaluation of Senofilcon A With New UV-blocker on a Neophyte Population

Inclusion criteria

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:

• The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Between 18 and 39 (inclusive) years of age at the time of screening.
• They are a contact lens 'neophyte'. In this work 'neophyte' is taken to mean any subject who has never been dispensed contact lenses. A subject who had taken part in a non-dispensing clinical study or had been fitted with contact lenses in practice but never went on to actually wear the lenses, is also classified as a 'neophyte'.
• Habitual spectacles must have resulted from an eye exam within the past six months.
• The subject must have worn the updated spectacles for at least two weeks.
• Be a current wearer of prescription spectacles that provide corrected monocular visual acuity of 20/25 or better in each eye.
• The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D (inclusive) in each eye.
• The subject's refractive cylinder must be -1.00 D or less in each eye.
• Have spherocylindrical best corrected distance Snellen visual acuity of 20/25 or better in each eye.

Exclusion criteria

• Potential subjects who meet any of the following criteria will be excluded from participating

• Currently pregnant or lactating.
• Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
• Use of systemic medications that have a high likelihood to interfere with contact lens wear (estrogens, antihistamines, anticholinergics, beta-blockers, and psychotropics).
• Any current use of ocular medication.
• Any known hypersensitivity or allergic reaction to any ingredient in Opti-Free PureMoist.
• Any previous or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
• Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
• Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
• Any Grade 3 or 4 slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA slit lamp classification scale.
• Binocular vision abnormality or strabismus.